Dossier
clinicaltrials
trial early
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Key claim: This study will evaluate the long-term effects of oral SAR302503 (TG101348, fedratinib) in myelofibrosis patients who completed the prior MF-TG101348-001 trial.
Abstract
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Why this matters
This study will evaluate the long-term effects of oral SAR302503 (TG101348, fedratinib) in myelofibrosis patients who completed the prior MF-TG101348-001 trial.